Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $876K fell 24.5% year over year, behind the +44.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 20.8% from the prior quarter.
Context
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -24.5% toward the trailing-twelve-month pace of +44.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 5.13M USD
- Year-over-year change
- +133.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.13M | +133.7% |
| FY2024 | 2024-12-31 | 2.2M | +961.4% |
| FY2023 | 2023-12-31 | 207K | +109.4% |
| FY2022 | 2022-12-31 | (2.2M) | — |
Other Income / Expenses vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 other income / expenses of $4.85M is the 6th highest of the 11 companies compared; the peer median is $4.15M.
- Its year-over-year change of +44.2% is the 3rd highest of 11, against a peer median of -35.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.16M | +37.9% | +80.4% | 10.1% | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $6.06M | +52.8% | — | — |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
| LTM Mar 2026 | $4.85M | +44.2% | — | — | |
| LTM Mar 2026 | $2.85M | -27.9% | +11.8% | 1268.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.76M | +155.6% | — | — |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$5.41M | -104.4% | — | 9176.3% | |
| Peer median (excluding AARD) | $4.15M | -35.6% | +11.5% | 19.3% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| Weighted Avg Shares | 21.38M | 21.38M | 21.7M | 21.82M |
| Weighted Avg Shares (Diluted) | 21.38M | 21.38M | 21.7M | 21.82M |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.